Skip to content

PECS Study for CIED Implantation Surgery

Pectoral Nerve (PECS) Block for Cardiac Implantable Electronic Devices (CIED) Implantation Surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04577690
Enrollment
48
Registered
2020-10-08
Start date
2019-12-01
Completion date
2028-01-01
Last updated
2026-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent, Child, Pain, Postoperative

Brief summary

We aim to determine whether pectoral nerve block (PECS) performed after induction of anesthesia but before surgical incision results less opioid use in the post operative period compared with local infiltration alone in children undergoing Cardiac Implantable Electronic Device (CIED) surgery.

Detailed description

The current anaesthetic management of CIED surgery at Sickkids is local anaesthetic infiltration by the EP cardiologist or a Pectoral nerve block (PECS) on an ad-hoc basis depending on the anaesthesiologist on a case by case basis. It is not known whether one technique provides better post- operative pain control and fewer adverse events than the other. In either case, the patient receives opioids as required during and after the procedure. Patients typically go home with a prescription for opioids to be taken for the first few days after surgery. The PECS block is a recognized effective anaesthetic technique used for both intraoperative and postoperative pain control in adult breast surgery, chest wall procedures as well as one case report for CIED implantation and a small series in paediatric cardiac surgery. The advantages of the PECS block in these surgical procedures includes improved analgesia and reduced opioid use. The investigators plan to conduct an RCT with two groups. Group 1 will receive a PECS block (using 0.8 ml/kg of 0.25% bupivacaine with epinephrine 1: 200000 divided in two equal volumes between the two planes) by the anaesthesiologist and local infiltration (up to 0.2 ml/kg of 0.25% bupivacaine with epinephrine 1:200000) by the surgeon. Group 2 will receive local infiltration (up to 0.8 ml/kg 0.25 % bupivacaine with epinephrine 1:200000) by the surgeon alone. Both groups will be given opioids as rescue analgesics as deemed necessary during their procedure and as rescue analgesia postoperatively, so that no patient will have untreated pain.

Interventions

DRUGBupivacaine 0.25% with epinephrine 1:200000 by PECS block and wound infiltration

The anesthesiologist will administer bupivacaine 0.25% with epinephrine 1:200000 by PECS block after induction of anesthesia before surgical incision. The EP cardiologist will also administer bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.

DRUGBupivacaine 0.25% with epinephrine 1:200000 by wound infiltration only

The EP cardiologist will administer Bupivacaine 0.25% with epinephrine 1:200000 by infiltrating the wound after surgery is complete.

Sponsors

The Hospital for Sick Children
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

The nursing staff in the post anesthesia care unit, patient and outcome assessors will be blinded to the patient allocation.

Intervention model description

Using a computer-generated table, patients will be randomized to one of two groups: PECS block or Local infiltration only. Group allocation are concealed in sealed, opaque, sequentially numbered envelopes that are opened on the day of surgery.

Eligibility

Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

• All patients 3-18 years undergoing CIED surgery in the chest

Exclusion criteria

* Children \< 3 years of age at time of procedure as bupivacaine is not licensed for this age group. * No parental or patient consent * Allergy to bupivacaine * Pregnancy or lactation * Any condition or diagnosis, that could in the opinion of the Principal Investigator or delegate interfere with the participant's ability to comply with study instructions, might confound the interpretation of the study results, or put the participant at risk.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative morphine consumption0 hoursAmount of morphine or morphine equivalents used after surgery

Secondary

MeasureTime frameDescription
Severity of pain0 hours, 6 hours, 12 hours and at discharge from hospitalSeverity of pain will be measured using and Numerical Rating Score (NRS) or Face, Legs, Activity, Cry and Consolability (FLACC) score as appropriate for age.
Incidence of nausea/emesis postoperativelyUntil discharge from recovery room, assessed up to 2 daysAny self-reported episodes of nausea and any emesis will be recorded
Incidence of pruritusUntil discharge from recovery room, assessed up to 2 daysAny self-reported episodes of pruritus will be recorded.
Adverse eventsUntil discharge from recovery room, assessed up to 2 daysAny occurrence of hematoma, pneumothorax, lung injury or local anesthesia toxicity will be recorded
Time to discharge from recovery roomUntil discharge from recovery room, assessed up to 2 daysTime from admission to recovery room to discharge from recovery room

Countries

Canada

Contacts

CONTACTKatherine Taylor
katherine.taylor@sickkids.ca416-813-7445
CONTACTCarolyne Pehora
carolyne.pehora@sickkids.ca416-813-7654
PRINCIPAL_INVESTIGATORKatherine Taylor

The Hospital for Sick Children

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 24, 2026